StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck organon — Renflexis (infliximab-abda biosimilar) U.S. sales ($M) ($M)

Organon & Co. Form 10-Q / 10-K (CIK 0001821825)

QuarterlyAnnual
Latest, Q2 2026
44,000,000
Period ended Jun 30, 2026
Change on a year earlier
-4.3%
46,000,000 in Q2 2025
History
22 quarters
Since Q1 2021
Sources
17
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOrganon — Renflexis (infliximab-abda biosimilar) U.S. sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202644,000,000-4.3%Organon & Co. SEC Filing (0001628280-26-051230) ↗
Q1 2026Mar 31, 202642,000,000-4.5%Organon & Co. SEC Filing (0001628280-26-029532) ↗
Q4 2025Dec 31, 202542,000,000-19.2%Organon & Co. SEC Filing (0001628280-26-011125) ↗
Q3 2025Sep 30, 202551,000,000-8.9%Organon & Co. SEC Filing (0001628280-25-050795) ↗
Q2 2025Jun 30, 202546,000,000-17.9%Organon & Co. SEC Filing (0001821825-25-000066) ↗
Q1 2025Mar 31, 202544,000,000-20.0%Organon & Co. SEC Filing (0001821825-25-000023) ↗
Q4 2024Dec 31, 202452,000,000-16.1%Organon & Co. SEC Filing (0001821825-25-000006) ↗
Q3 2024Sep 30, 202456,000,000-1.8%Organon & Co. SEC Filing (0001821825-24-000108) ↗
Q2 2024Jun 30, 202456,000,000-6.7%Organon & Co. SEC Filing (0001821825-25-000066) ↗
Q1 2024Mar 31, 202455,000,0000.0%Organon & Co. SEC Filing (0001821825-25-000023) ↗
Q4 2023Dec 31, 202362,000,000+21.6%Organon & Co. SEC Filing (0001821825-25-000006) ↗
Q3 2023Sep 30, 202357,000,000+5.6%Organon & Co. SEC Filing (0001821825-24-000108) ↗
Q2 2023Jun 30, 202360,000,000+17.6%Organon & Co. SEC Filing (0001821825-24-000083) ↗
Q1 2023Mar 31, 202355,000,000+31.0%Organon & Co. SEC Filing (0001821825-24-000056) ↗
Q4 2022Dec 31, 202251,000,000+13.3%Organon & Co. SEC Filing (0001821825-25-000006) ↗
Q3 2022Sep 30, 202254,000,000+12.5%Organon & Co. SEC Filing (0001821825-23-000013) ↗

Cite this data

StockData. (2026). Merck Organon — Renflexis (infliximab-abda biosimilar) U.S. sales ($M) ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn_renflexis_us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.